Pharma giant Sanofi charged with manslaughter in birth defects case

Pharma giant Sanofi charged with manslaughter in birth defects case

Monday, August 03, 2020

Print this page Email A Friend!


PARIS, France (AFP) — French prosecutors have indicted pharma giant Sanofi for manslaughter over birth defects linked to an epilepsy drug, the company said Monday, in a long-running case that has also seen it charged with fraud.

The charges relate to the drug valproate, marketed as Depakine among other trade names, which studies say has caused disabilities in about 15,000-30,000 children whose mothers took the medicine while pregnant.

On the market since 1967, the drug is used to treat epilepsy, migraines and bipolar disorder.

But research found that when pregnant women took the drug, their children had an elevated risk -- between 10 to 40 per cent -- of congenital malformations, autism and learning difficulties.

Sanofi is facing separate charges of aggravated fraud and unintentionally causing injury in 42 cases filed by families, but insists it had warned health authorities of the drug's risks already in the 1980s.

On Monday, the company confirmed a report in Le Monde newspaper that prosecutors have now also charged it with manslaughter.

But in a statement sent to AFP it insisted it had "fulfilled its obligation" of providing information on the drug and its side-effects, and said it "contests the validity of these proceedings."

Sanofi said it has filed a legal challenge to the indictment.

Under the French legal system, charges do not automatically result in a trial as prosecutors can decide not to proceed based on a lack of evidence.

Last month, a French court ordered the state to pay thousands of euros in damages over the scandal, saying officials should have ensured the drug was not taken by pregnant women.

The court found that health officials knew about the risk of birth defects from Depakine already in 1983, and of learning disabilities and autism from 2004.

Another 500 complaints have been lodged with France's national compensation agency for medical accidents, which has already proposed a 6.5-million-euro (US$7.6-million) package for Depakine victims.

Sanofi, a France-based multinational, is working on a candidate vaccine against the novel coronavirus with Britain's GSK, for which it will receive up to US$2.1 billion from the US government.

á


Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at http://bit.ly/epaper-login


ADVERTISEMENT




POST A COMMENT

HOUSE RULES

1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper ´┐Ż email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed: advertising@jamaicaobserver.com.

6. If readers wish to report offensive comments, suggest a correction or share a story then please email: community@jamaicaobserver.com.

7. Lastly, read our Terms and Conditions and Privacy Policy



comments powered by Disqus
ADVERTISEMENT

Poll

ADVERTISEMENT
ADVERTISEMENT

Today's Cartoon

Click image to view full size editorial cartoon
ADVERTISEMENT